UCB's Global Corporate Website

This section is intended for media and financial analysts

Search Press releases

15 Mar 2024

UCB announces changes on Board of Directors

Read More
13 Mar 2024

UCB successfully completes institutional Eurobond issue

Read More
9 Mar 2024

First presentation of four-year BIMZELX[®](bimekizumab-bkzx) data showed long-term maintenance of complete skin clearance in moderate to severe plaque psoriasis

Read More
8 Mar 2024

Bimekizumab 48-week Phase 3 analyses in moderate to severe hidradenitis suppurativa showed sustained improvements in skin pain and draining tunnel count

Read More
4 Mar 2024

UCB announces strategic investment in IMIDomics, Inc to advance breakthrough solutions for immune-mediated inflammatory diseases

Read More
28 Feb 2024

UCB on Growth Path for a Decade Plus

Read More

Stay up-to-date on the latest news and information from UCB